scispace - formally typeset
B

Bo Lu

Researcher at Ohio State University

Publications -  390
Citations -  24905

Bo Lu is an academic researcher from Ohio State University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 58, co-authored 353 publications receiving 21823 citations. Previous affiliations of Bo Lu include Wuhan University of Technology & Wuhan University.

Papers
More filters
Journal ArticleDOI

Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer.

TL;DR: The report suggests that combined inhibition of apoptosis and mTOR during radiotherapy is a potential therapeutic strategy to enhance radiation therapy in patients with non-small cell lung cancer.
Journal ArticleDOI

Fabrication of supramolecular hydrogels for drug delivery and stem cell encapsulation.

TL;DR: The in vitro cell viability studies and the in vivo histological studies demonstrated that the hydrogels were non-cytotoxic and biocompatible, which indicated that thehydrogels prepared were promising candidates as injectable scaffolds for tissue engineering applications.
Journal ArticleDOI

Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer

TL;DR: It is found that 3 Gy significantly reduced survivin protein level in human umbilical vein endothelial cells (HUVECs) but not in tumor cell lines, which suggests that survivin may be a target for cancer therapy.
Journal ArticleDOI

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer

TL;DR: Potential pathways to target ALK-rearranged brain metastases are discussed, including next generation ALK inhibitors with greater CNS penetration and mechanisms to overcome resistance.
Journal ArticleDOI

Galactosylated fluorescent labeled micelles as a liver targeting drug carrier

TL;DR: The in vivo study demonstrated the relative uptake of the micelles by liver is much higher than the other tissues, indicating that the galactosylated micells have great potential as a liver targeting drug carrier.